A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
Clinical trial NCT00910858 · COMPLETED
Trial details
- NCT number
- NCT00910858
- Sponsor
- Celgene Corporation
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2005-01-01
- Primary completion
- 2006-04-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.